[Hydroxylation of debrisoquin in Parkinson's disease]
- PMID: 2141131
[Hydroxylation of debrisoquin in Parkinson's disease]
Abstract
The accumulation of environmental substances, due to deficiency of liver detoxication processes, is one of the hypotheses put forward in the search of the cause of Parkinson's disease. The debrisoquine test was used to evaluate the capacity for hydroxylation of twenty patients treated for Parkinson's disease. No difference was found with the results obtained in non Parkinsonians: other metabolic pathways, notably S-methylation, should be explored.
Similar articles
-
Diurnal effects on debrisoquine hydroxylation phenotyping.Eur J Clin Pharmacol. 1988;35(4):441-2. doi: 10.1007/BF00561381. Eur J Clin Pharmacol. 1988. PMID: 3197754
-
Polymorphic 4-hydroxylation of debrisoquine in chronic discoid psoriasis.Eur J Clin Pharmacol. 1981;21(3):257-8. doi: 10.1007/BF00627929. Eur J Clin Pharmacol. 1981. PMID: 6895622 No abstract available.
-
Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine.Lancet. 1985 Nov 30;2(8466):1213-6. doi: 10.1016/s0140-6736(85)90743-3. Lancet. 1985. PMID: 2866293
-
Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators.Psychopharmacol Ser. 1989;7:201-5. doi: 10.1007/978-3-642-74430-3_21. Psychopharmacol Ser. 1989. PMID: 2687858 Review. No abstract available.
-
Abnormal liver enzyme-mediated metabolism in Parkinson's disease: a second look.Neurology. 1991 May;41(5 Suppl 2):89-91; discussion 92. doi: 10.1212/wnl.41.5_suppl_2.89. Neurology. 1991. PMID: 2041601 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical